Romosozumab and antiresorptive treatment: the importance of treatment sequence-Reference-Cited by-同舟云学术

Romosozumab and antiresorptive treatment: the importance of treatment sequence

Published:2022-02-15 Issue:6 Volume:33 Page:1243-1256
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

Cosman Felicia^ORCID,Kendler David L.,Langdahl Bente L.,Leder Benjamin Z.,Lewiecki E. Michael,Miyauchi Akimitsu,Rojeski Maria,McDermott Michele,Oates Mary K.,Milmont Cassandra E.,Libanati Cesar,Ferrari Serge

Funder

Amgen Inc.

UCB Pharma

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00198-021-06174-0.pdf

Reference56 articles.

1. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039

2. Saag KG, Zanchetta JR, Devogelaer J-P, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six–month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355

3. Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150

4. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240

5. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Essential Osteoporosis Management for the Primary Care Provider;Canadian Primary Care Today;2024-09-09

2. Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis;Journal of Orthopaedic Translation;2024-09

3. Comment on: A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis;Osteoporosis International;2024-08-09

4. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024;Journal of Bone and Mineral Research;2024-07-29

5. What’s New in Osteoporosis: Emphasis on the Aging Athlete;Journal of Bone and Joint Surgery;2024-07-25